Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales.

Ceftazidime-avibactam is a novel combination of a known cephalosporin and a non-β-lactam/β-lactamase inhibitor that has been approved for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia as well as Gram-negative infections with limited treatment options in Europe. Since its approval, it has been used in patients with infections due to carbapenem-resistant bacteria, in many occasions as off-label indication or salvage therapy, with promising clinical and microbiological cure rates. Emergence of resistance during therapy to this new combination has already been described, which is a matter of concern. A rational use of these new therapeutic options is critical in the multidrug resistance era. The current review focuses on the clinical experience in real life of ceftazidime-avibactam use in the treatment of carbapenemase-producing Enterobacterales.

• Publication year

  2020

• Venue

  Future Microbiology

• Publication date

  2020-04-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fmb-2020-0012PMID 32301348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients

  2019cited by this paper
• Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections

  2019cited by this paper
• Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

  2019cited by this paper
• Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.

  2019cited by this paper
• KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study.

  2019cited by this paper
• Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

  2019cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development

  2018cited by this paper
• Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase–producing K. pneumoniae

  2018cited by this paper
• Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

  2018cited by this paper
• Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

  2018cited by this paper
• Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups

  2018cited by this paper
• Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae

  2018cited by this paper
• A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.

  2017cited by this paper
• Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae

  2017cited by this paper
• Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.

  2017cited by this paper
• Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.

  2017cited by this paper
• Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment

  2017cited by this paper
• Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.

  2017cited by this paper
• Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration

  2017cited by this paper
• Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia

  2017cited by this paper
• The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace

  2017cited by this paper
• Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.

  2016cited by this paper
• Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing Klebsiella pneumoniae.

  2016cited by this paper
• Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

  2016cited by this paper
• Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis

  2016cited by this paper
• Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

  2016cited by this paper
• Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

  2016cited by this paper
• Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient.

  2016cited by this paper
• Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

  2016cited by this paper
• Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms

  2016cited by this paper
• Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.

  2015cited by this paper
• Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies

  2015cited by this paper
• Multidrug-resistant Gram-negative bacteria: a product of globalization.

  2015cited by this paper
• The β‐Lactams Strike Back: Ceftazidime‐Avibactam

  2015cited by this paper
• DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

  2014cited by this paper
• Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation.

  2014cited by this paper
• Oral Gentamicin Gut Decontamination for Prevention of KPC-Producing Klebsiella pneumoniae Infections: Relevance of Concomitant Systemic Antibiotic Therapy

  2014cited by this paper
• Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.

  2013cited by this paper
• Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia.

  2013cited by this paper
• Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe.

  2012cited by this paper
• Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor

  2012cited by this paper
• Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

  2012cited by this paper
• Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

  2008cited by this paper
• Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern

  2008cited by this paper
• Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.

  2007cited by this paper
• Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers

  2005cited by this paper
• REVIEWS OF ANTI-INFECTIVE AGENTS: Louis Saravolatz, Section Editor OF ANTI-INFECTIVE AGENTS Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations

  year unknowncited by this paper

• Evolution of Antibiotic Resistance and Virulence in ST11-KL64 Carbapenem-Resistant Klebsiella pneumoniae Under Last-Resort Antibiotic Pressure.

  2026cites this paper
• Evolution of ceftazidime-avibactam resistance driven by variation in bla KPC-2 to bla KPC-190 during treatment of ST11-K64 hypervirulent Klebsiella pneumoniae

  2025cites this paper
• Assessment of carbapenemase genes and antibiotic resistance profiles in ceftazidime–avibactam resistant Klebsiella pneumoniae isolates: A single-center cross-sectional study

  2025cites this paper
• A Real‐World Pharmacovigilance Study of Ceftazidime/Avibactam: Data Mining of the Food and Drug Administration Adverse Event Reporting System Database

  2024cites this paper
• Development of an effective meropenem/KPC-2 inhibitor combination to combat infections caused by carbapenem-resistant K. pneumoniae.

  2024cites this paper
• Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae

  2024cites this paper
• Genomic and epidemiological insight of an outbreak of carbapenemase-producing Enterobacterales in a Portuguese hospital with the emergence of the new KPC-124.

  2023cites this paper
• Ceftazidime–avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis

  2023cites this paper
• Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates

  2023cites this paper
• Antibiotics in the clinical pipeline as of December 2022

  2023cites this paper
• Bloodstream Infection and Gram-Negative Resistance: The Role for Newer Antibiotics

  2023cites this paper
• Carbapenem-Resistant Klebsiella pneumoniae: Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options

  2023cites this paper
• The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.

  2023cites this paper
• Simultaneous Determination of Ceftazidime and Avibactam in Human Plasma and Cerebrospinal Fluid by High-Performance Liquid Chromatography – Tandem Mass Spectrometry (HPLC-MS/MS)

  2022cites this paper
• Assessment of In vitro Activities of Ceftaroline, Ceftazidime/ avibactam and Colistin against different Gram Negative and Gram Positive Isolates

  2022cites this paper
• Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria

  2022cites this paper
• Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM.

  2022cites this paper
• Multiple Novel Ceftazidime-Avibactam-Resistant Variants of blaKPC-2-Positive Klebsiella pneumoniae in Two Patients

  2022cites this paper
• Diversity of Ceftazidime-Avibactam Resistance Mechanism in KPC2-Producing Klebsiella pneumoniae Under Antibiotic Selection Pressure

  2022cites this paper
• Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review

  2022cites this paper
• Antibacterial activity and carbapenem re‐sensitizing ability of 1,10‐phenanthroline‐5,6‐dione and its metal complexes against KPC‐producing Klebsiella pneumoniae clinical strains

  2021cites this paper
• Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections

  2021cites this paper
• Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review

  2021cites this paper
• Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?

  2021cites this paper
• Effectiveness of Ceftazidime-Avibactam versus Colistin in Treating Carbapenem-Resistant Enterobacteriaceae Bacteremia.

  2021cites this paper
• Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.

  2021cites this paper
• Resistance to ceftazidime/avibactam in infections and colonizations by KPC-producing Enterobacterales: a systematic review of observational clinical studies.

  2021influential citation
• The role of new antimicrobials for Gram-negative infections in daily clinical practice

  2020cites this paper
• Carbapenemase-producing Enterobacterales: changing epidemiology in a highly endemic Italian area.

  2020cites this paper
• Infections Caused by Carbapenem-Resistant Enterobacterales: Epidemiology, Clinical Significance, and Possibilities for Antibiotic Therapy Optimization

  2020cites this paper
• Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance

  2020cites this paper